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creativecommons.org/mine the effect of screening for dementia in primary care practices on the formal diagnosis rate; the
distribution of differential diagnoses; and the factors associated with receiving a formal diagnosis.
Methods: The “Dementia: life- and person-centered help in Mecklenburg-Western Pomerania” is an
ongoing general practitioner (GP)-based, randomized, controlled intervention trial. A total of 4064
community dwelling patients (aged 70 years) were screened for dementia in 108 GP practices.
Of these patients, 692 (17%) had positive screening results (DemTect score ,9). Of these 692 pa-
tients, 406 (59%) provided informed consent. The analyses included the data from 243 patients
with a complete baseline assessment (preliminary data; January 2014).
Results: Of 146 patients without a formal diagnosis of dementia, 72 (49%) received a formal diag-
nosis after a positive screening outcome (69% with “unspecified dementia”). Female sex was signif-
icantly associated with receiving a formal diagnosis (multivariate analyses).
Conclusion: Screening improved the identification of dementia considerably. Because of the risk of
receiving a false-positive diagnosis, additional diagnostic assessment should be mandatory.
 2015 The Alzheimer’s Association. Published by Elsevier Inc. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords: Dementia; Screening; Recognition; Early diagnosis; Differential diagnosis; Primary care; Diagnosis rate; DelpHitrial1. Introduction
A timely diagnosis of dementia is considered of major
importance to ensure adequate access to information,
evidence-based treatment, care, and support for people
with dementia [1]. However, even in high-income countries
with advanced medical care systems, 50% to 80% of all
prevalent dementia cases are not formally diagnosed [1–3].
The screening of older patients for cognitive impairment
could be a method to improve the recognition of dementia.
Previous studies have shown that screening for dementia inthor. Tel.: 49-3834-867591; Fax: 49-3834-8619551.
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licenses/by-nc-nd/4.0/).general practitioners’ (GPs) practices did increase the
diagnosis rates [4,5]. Nevertheless, routine screening for
dementia has been controversial and is not presently
recommended in the dementia guidelines owing to the lack
of evidence that patients benefit from it [6–8]. In addition,
patients with positive screening results often undergo no
additional diagnostic assessment and do not receive
specific treatment [4,5]. For the benefit of patients, a
positive screening outcome should initiate an adequate
diagnostic assessment and, depending on the results, state
of the art treatment and care. Furthermore, screening could
result in potential harms [9–12]. Older patients might
avoid visiting their GP because they fear to be diagnosed
with dementia. Also, false-positive screening resultshis is an open access article under the CC BY-NC-ND license (http://
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necessary examinations and treatments, and might cause
anxiety and depression in the affected subjects. Boustani
et al [13] showed that the probability of false-positive
screening results is relatively high: about 20% of patients
who screened positive for dementia did not have dementia
at all and another 30% had mild cognitive impairment. Sand-
holzer et al [5] examined the acceptance of screening among
German primary care patients and found that 89% of the
screened patients considered the screening to be useful.
Only 1.5% of the patients reported that they worried more
about their health after the screening. Other surveys revealed
that a clear majority of participants would prefer to be diag-
nosed early and expected to be properly informed about their
diagnosis [14,15].
Initiatives have been implemented to improve the recog-
nition of dementia, such as the “Annual Wellness Visit” for
Medicare enrollees in the United States that includes the
detection of any cognitive impairment [16]. Also, the proac-
tive “dementia case finding scheme” was initiated by the
government of the United Kingdom, aiming to increase the
diagnosis rate of dementia and to improve dementia treat-
ment and care on the population level [17]. No recent data
are available about the effect that screening for dementia
would have on the diagnostic process in German primary
care practice. Thus, the present research report aims to
contribute empirical findings to (1) the effect of a screening
test for dementia in German primary care practices on the
rate of a formal diagnosis of dementia; (2) the distribution
of etiologies of newly assigned diagnoses after a screening
for dementia; and (3) the factors associated with receiving
a formal diagnosis of dementia after a positive dementia
screening test.2. Methods
2.1. Study design
The present cross-sectional analyses were performed on
data derived from the ongoing GP-based, randomized,
controlled intervention trial, Dementia: life- and person-
centered help in Mecklenburg-Western Pomerania
(DelpHi-MV). The details of the study have been previously
reported [18]. The eligible patients (aged .70 years and
living at home) were screened for dementia at participating
GP practices using DemTect [19]. This personal interview-
based instrument includes five tasks (recall of a word list,
number transcoding task, word fluency task, digit span
reverse, delayed recall of word list) and is widely used for
dementia screening in general practices in Germany [20].
The patients who meet the inclusion criteria for the
DelpHi trial (DemTect score ,9) were informed by their
GPs about the study, invited to participate, and asked to pro-
vide written informed consent. If the patient named a care-
giver, the caregiver was asked to participate in the study.
When patients were unable to givewritten informed consent,their legal representative was asked to sign the consent form
on their behalf (as approved by the Ethical Committee of the
Chamber of Physicians of Mecklenburg-Western Pomera-
nia, registry number BB 20/11). The study physicians
received allowances for performing the screening test
(10V per patient) and study enrollment (100V per patient).
Study enrollment into the main study began January 1,
2012. The participants and their caregivers were assigned
to an intervention or a control group, depending on whether
the treating GP practice had been randomized to the control
or intervention group. In both groups, identical, standard-
ized, computer-assisted baseline assessments were conduct-
ed as face-to-face interviews at the participants’ homes.
After the baseline assessment, the intervention group
received the “DelpHi-Intervention” (for a detailed descrip-
tion of the DelpHi-Intervention, see Eichler et al [21]). In
contrast, the control group received “care as usual.” The
ClinicalTrials.gov identifier is NCT01401582.2.2. Study population
A total of 4064 patients were screened for dementia in
108 participating GP practices. Of these, 692 patients
(17%) were eligible for the DelpHi trial, and 406 patients
(59%) agreed to participate in the study. However, 90 partic-
ipants either did not start the baseline assessment or had not
finished all parts of the assessment at the time of the
analyses.
Fifty-eight patients were withdrawn from the analyses
owing to withdrawal of informed consent (n 5 31), death
(n5 20), relocation (n5 3) or other reasons (n5 4). No sta-
tistically significant differences were found between the pa-
tients included in the analyses and those who withdrew for
DemTect score, age, and sex (see Supplemental Table 1,
available online).
Fifteen patients were excluded because the psychometric
instruments could not be used (the patients were unable to
answer the questions because of the severity of dementia
or the patients had refused to answer for other reasons).
The patients included in the analyses had significantly
higher DemTect scores than those patients excluded because
of missing data (mean 5.84 6 2.02 versus 3.73 6 2.34;
Welch’s t test, t(15.50) 5 3.41; P , .01). Regarding age,
sex, and a formal diagnosis of dementia, we found no signif-
icant differences (see Supplemental Table 2, available
online).
The complete baseline assessment regarding relevant var-
iables was available for 243 patients (January 1, 2014, pre-
liminary data). Of the 243 patients, 97 (40%) had been
formally diagnosed with dementia by their GP before the
screening (53% unspecified dementia; 24% vascular demen-
tia; 19% Alzheimer’s disease). Patients with a formal diag-
nosis had a significantly lower score on the DemTect
(mean 5.43 6 2.09 versus 6.11 6 1.94; Welch’s t test,
t(196.42)5 2.57, P5 .01) and the Mini Mental State Exam-
ination (MMSE) [22] than patients not previously diagnosed
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Welch’s t test, t(181.49)5 3.84, P, .001). A detailed com-
parison of the patients with and without a formal diagnosis
of dementia before screening can be found in the study by
Eichler et al [3]. The presented analyses were based on
data from 146 patients without a formal diagnosis of demen-
tia before screening.2.3. Procedures and instruments
For the sample description, patient age, sex, living situa-
tion (alone versus not alone), cognitive status, depression,
and functional status were analyzed. Cognitive status was as-
sessed using the German version of the MMSE [22]. In the
analyses, we used the total MMSE score and a categorization
indicating “no cognitive impairment” (score 27–30), “mild”
(score 20–26), “moderate” (score 10–19), and “severe cogni-
tive impairment” (score 0–9). Depression was operational-
ized using the score of the Geriatric Depression Scale
[23,24] as a dichotomized variable (“no depression,” score
0–5; “depression,” score 6–15). The functional status was
assessed using the Bayer Activities of Daily Living Scale
[25,26], which yields a mean score of 1 to 10, where 1
indicates the lowest possible impairment and 10 the
highest possible impairment. For all patients who had
provided the respective informed consent, the formal
medical diagnoses (International Classification of Disease,
version 10, codes F00, F01, F02, F03, G30, and G31) were
retrieved from the medical records in the GP practice
(including the exact date of the initial diagnosis).2.4. Statistical analysis
We summarized the variables that describe the sample us-
ing descriptive statistics. To assess the effect of screening on
the formal diagnosis rate, we categorized the patients into
two groups: patients diagnosed after screening (all patients
who had received a formal diagnosis of dementia between
the day of screening and the baseline assessment) and pa-
tients not diagnosed after screening (all patients who had
not received a formal diagnosis between the day of screening
and the baseline assessment). To test for the differences be-
tween those groups, we usedWelch’s t test (robust to unequal
variances) for continuous and Fisher’s exact test for catego-
rized variables. To identify the factors associated with the
assignment of a diagnosis of dementia after screening, we
fitted a logistic regression model, including age, sex, living
situation, cognitive impairment, depression, and functional
status. Because DelpHi-MV is a cluster-randomized trial,
the dependency of data from participants who belonged to
the same cluster (i.e., the same treating GP) had to be consid-
ered. Therefore, we applied a conditional (fixed effect) logis-
tic regression model, which offers consistent estimates in
cases of clustered data [27,28]. Before running the final
regression model, we checked for nonlinear relations using
the multivariate fractional polynomial procedure [29]. Wefound no indication for nonlinear relations; thus, these pre-
dictors were included in linear terms. The chosen estimation
procedure excluded 60 observations because of the invari-
ance in the outcome variable in certain clusters (i.e., all or
none of the patients treated by the same GP were formally
diagnosed with dementia). We found no significant differ-
ences between the included and these excluded cases
regarding the analyzed variables (see Supplemental
Table 3, available online). The final regression analysis
was performed on the remaining 86 patients assigned to 15
clusters (the clusters were unbalanced). Standard errors of
the regression coefficients were estimated using the jack-
knife method, which allows one to estimate standard errors
in complex samples [30]. Statistical analyses were per-
formed using Stata/IC [31].3. Results
3.1. Sociodemographic and clinical characteristics
The sociodemographic and clinical characteristic of the
study sample are listed in Table 1.3.2. Effect of screening on receiving a formal diagnosis
Of 146 patients who had not been formally diagnosed
before screening, 72 (49%) received at least one formal diag-
nosis of dementia after a positive DemTect screening. Of
these, 38 (53%) received the formal diagnosis on the day
of the screening.3.3. Distribution of differential diagnoses
The distribution of newly assigned differential diagnoses
after screening is shown in Figure 1. “Unspecified dementia”
was by far the most often assigned diagnosis; 69% of the pa-
tients received this diagnosis. This proportion was still
higher in the patients who received their diagnosis at the
day of screening (74%).3.4. Factors associated with receiving a formal diagnosis
of dementia after positive DemTect screening
Univariate statistical analyses revealed that patients who
had received a formal diagnosis of dementia after screening
were significantly more often women (74% versus 51%) and
were significantly more often severely impaired regarding
their cognitive (MMSE) and functional status (Bayer Activ-
ities of Daily Living Scale; Table 1).
In the multivariate conditional logistic regression ana-
lyses, the only factor significantly associated with receiving
a formal diagnosis of dementia after screening was female
sex [F(6,14) 5 3.68, P , .05]. The chance of receiving a
formal diagnosis after a positive DemTect screening was
more than five times greater for women than for men
(odds ratio 5.42; P , .01; 95% confidence interval 1.93–
15.22). The results are listed in Table 2.
Table 1
Sociodemographic and clinical characteristics of the study sample
Variable Total sample (n 5 146)
Formally diagnosed after screening
t df P valueNo (n 5 74) Yes (n 5 72)
Female sex 91 (62) 38 (51) 53 (74) — — ,.01*
Age (y) 79.58 6 5.32 79.30 6 4.98 79.88 65.66 0.65 142.56 .51y
Living alone 66 (45) 31 (42) 35 (49) — — .51*
Cognitive impairment (MMSE) 23.14 6 4.96 24.26 6 4.83 22.00 6 4.87 2.81 145.81 ,.01y
None (score 27–30) 52 (37) 35 (47) 17 (24) ,.02*
Mild (score 20–26) 56 (38) 24 (32) 32 (44)
Moderate (score 10–19) 32 (22) 13 (18) 19 (26)
Severe (score 0–9) 6 (4) 2 (3) 4 (6)
Depression (GDS 6) 36 (25) 18 (24) 18 (25) — — 1.00*
Functional status (B-ADL) 3.26 6 2.23 2.73 6 2.01 3.80 6 2.33 2.97 141.54 ,.01y
Abbreviations: MMSE, Mini Mental State Examination (range 0–30; higher score indicates better cognitive functioning); B-ADL, Bayer Activities of Daily
Living Scale (range 0–10; lower score indicates better performance); GDS, Geriatric Depression Scale (sum score 0–15; score 6 indicates depression).
NOTE. Data presented as n (%) or mean 6 standard deviation.
*Fisher’s exact test.
yWelch’s t test.
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The present analysis revealed a strong effect of screening
for dementia among German primary care patients on the
probability of receiving a formal diagnosis of dementia.
Almost 50% of previously undiagnosed patients received a
formal diagnosis of dementia after they had screened positive
at their GP practice. The overall diagnosis rate in primary care
patients who had screened positive for dementia increased
from 40% before screening [3] to 70% after screening.
Thus, our findings indicate that a considerable number of pa-
tients with cognitive impairment might not be recognized by
their GP without a cognitive test. The results of the multivar-
iate analysis showed that the chance of receiving a formal
diagnosis after a positive DemTect screening was more thanFig. 1. Differential diagnoses of dementia in primary care patients formally
diagnosed after they have screened positive for dementia (n 5 72).five times higher in woman than in men; thus, women, in
particular, might benefit from screening.
Previous research has demonstrated that physicians often
do not recognize cognitive impairment, even in those with
severe dementia [1,13,32,33]. For German primary care
patients, Sandholzer et al [5] showed that the prevalence of
cognitive impairment in patients aged 70 years or older
was 4.6% according to the GP diagnosis but 21% according
to the MMSE score.
Our results have provided evidence that routine screening
can improve the identification of dementia considerably. To
the best of our knowledge, this study is the first to demon-
strate such a profound effect of screening, although previous
studies reported substantially smaller effects. Sandholzer
et al [5] found that only 6% of the German primary care pa-
tients who had screened positive for dementia had received
any diagnostic assessment or treatment. Borson et al [4]
showed that relevant physician behavior (i.e., a formal diag-
nosis of dementia, specialist referral, or cognitive enhancing
medication) occurred for only 17% of the positively
screened patients. A reason for the considerably high effect
of screening in the present study could have been the active
involvement of the participating GPs in a dementia interven-
tion trial that aimed to optimize treatment and care for peo-
ple with dementia. The GPs did not only receive information
about the result of the cognitive test. Furthermore, they
informed all positively screened patients about the DelpHi
trial and had obtained their informed consent for study
participation. This might have increased the perceived
importance of a positive screening outcome, which could
have led to an increased probability that the respective pa-
tients would receive a formal diagnosis of dementia. This
might have been a sort of clinical “Hawthorne effect” such
that the GPs might have changed their behavior because
they were participating in an intervention study [34,35].
According to the medical files of the participating GP
practices, more than 50% of the newly diagnosed patients
Table 2
Factors associated with receiving a formal diagnosis of dementia after screening
Variable
Formally diagnosed after screening
OR t P value 95% CINo (n 5 38) Yes (n 5 48)
Age (y) 80.08 6 5.35 80.13 6 5.15 0.92 0.85 .41 0.74–1.14
Female sex 17 (45) 37 (77) 5.42 3.51 ,.01 1.93–15.22
Living alone 11 (29) 25 (52) 1.02 0.03 .98 0.19–5.53
Cognitive impairment (MMSE) 24.00 6 5.28 21.87 6 4.63 0.93 1.23 .24 0.82–1.05
Functional status (B-ADL) 2.97 6 2.17 3.68 6 2.22 1.35 1.54 .15 0.89–2.04
Depression (GDS) 10 (26) 11 (23) 0.65 0.40 .69 0.07–6.42
Abbreviations: OR, odds ratio; CI, confidence interval; MMSE, Mini Mental State Examination (range 0–30; higher score indicates better cognitive func-
tioning); B-ADL, Bayer Activities of Daily Living Scale (range 0–10; lower score indicates better performance); GDS, Geriatric Depression Scale (sum score
0–15; score 6 indicates depression).
NOTE. Data presented as mean6 standard deviation or n (%). Conditional fixed effect logistic regression analysis (n5 86 patients assigned to n5 15 clus-
ters): F(6,14) 5 3.68, P , .05.
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In addition, the proportion of the diagnosis of “unspecified
dementia” as the only diagnosis was considerably high
(69% of all patients formally diagnosed after screening
and 74% of patients formally diagnosed at the day of
screening). This could imply that some GPs might assign a
formal diagnosis to patients because of a positive screening
result. However, our data did not provide any insight into the
process of assigning a formal diagnosis. A desired conse-
quence would be that a positive screening result would
initiate additional differential diagnostic assessments of
the patients. Without an adequate diagnostic assessment,
the risk of assigning a false-positive diagnosis of dementia
is high [13]. Reversible causes of cognitive impairment,
such as depression, vitamin B12 deficiency, or hypothyroid-
ism might remain unrecognized and therefore untreated.
In the present sample, 24% of the patients who screened
positive for dementia on the DemTect (score,9) received a
formal diagnosis of dementia but were not cognitively
impaired according to their MMSE result (score 27–30; as-
sessed at baseline). Some of these patients might have been
misdiagnosed. Because previous studies showed that the
MMSE is less sensitive for detecting milder forms of cogni-
tive impairment (43%–43%) [36] than the DemTect (80%–
100%) [19,37], the rate of false-positive diagnoses in our
study might have been lower than 24%. However, we were
unable to validate the GP diagnoses with our data. Neverthe-
less, analyzing our follow-up data will allow more detailed
information about which formal diagnosis will be confirmed
or changed in the course of the disease and what processes of
additional differential diagnostic and treatment will be fol-
lowed after the initial diagnosis.
The potential adverse effects of a false-positive diagnosis
must be weighed against the harm of overlooking dementia.
Recognizing and diagnosing dementia is an inevitable pre-
requisite for providing adequate information, treatment,
and care. Thus, although screening for dementia in elderly
patients has not yet been adopted in the dementia guidelines
[6–8], it could be a possibility to reduce the high rates of
unrecognized dementia. The requirements for an adequateprocedure to detect cognitive impairment in routine care
are currently being discussed. The Alzheimer’s
Association has proposed an algorithm to detect cognitive
impairment during the Medicare “Annual Wellness Visit”
in a primary care setting in the United States [16] that could
also be a possible strategy for primary care settings in other
countries. Because screening entails the risk that patients
will receive a false-positive diagnosis of dementia after
they have screened positive, additional diagnostic assess-
ments should be mandatory. Also, the proactive provision
of adequate treatment and care in the case of a confirmed
diagnosis should be fostered.
Currently, little evidence is available that shows improved
health outcomes for patients who have been formally diag-
nosed with dementia [9,38]. Regarding the potential adverse
effects of screening, no studies have yet directly addressed
the adverse psychological effects of screening or the adverse
effects of false-positive test results [38]. Thus, the potential
positive and negative consequences of screening for dementia
require systematic and comprehensive evaluation. Analyzing
our follow-up data will enable us to provide additional evi-
dence. In the DelpHi trial [18,21], the patient outcomes of
the control group receiving “care as usual” will be compared
with the outcomes of the intervention group receiving a
collaborative dementia care management after screening
positive for dementia. Thus, we will be able to determine the
effect of receiving a formal diagnosis of dementia after a
positive screening result on various outcomes (e.g.,
treatment and care, quality of life, psychological well being,
and health outcomes) in both groups.Acknowledgments
Author contributions: T.E. drafted the manuscript. J.R.T., the
study coordinator, contributed substantially to the overall
design and implementation of the DelpHi trial. J.H. (statisti-
cal analyses), B.M. (health economy), D.W. (pharmacy),
A.D. (nursing science), I.K. (neurology), and S.T. (psychia-
try) contributed to the DelpHi trial and the report in accor-
dance with their areas of expertise. W.H., the principal
T. Eichler et al. / Alzheimer’s & Dementia: Diagnosis, Assessment & Disease Monitoring 1 (2015) 87–9392investigator of the study, contributed substantially to the
concept of the DelpHi trial and the final version of the report.
All authors read and approved the final report.
Additional contributions: The DelpHi trial was developed
and established as a result of input from the following
experts in their respective fields: Aniela Angelow, Grit
Aßmann, Georgia B€owing, Adina Dreier, Thomas Fiß,
Daniel Fredrich, Leonore K€ohler, and Steffen Richter. An
experienced field study team provided support with data
collection and data management: Ines Abraham, Kerstin
Albuerne, Vaska B€ohmann, Kathleen Dittmer, Sarah
Gardzella, Jana Hubert, Ulrike Kempe, Viktoriya Kim, Katja
L€ubke, Andrea Pooch, Saskia Moll, Sabine Schmidt,
Christine Winckler, and Paula Winter. We also thank all
participating patients and their general practitioners for their
most valued collaboration.
The study was funded by the German Center for Neurode-
generative Diseases (DZNE) and the University Medicine
Greifswald.
Conflict of interest disclosure: The authors declare no con-
flicts of interest.Supplementary data
Supplementary data related to this article can be found at
http://dx.doi.org/10.1016/j.dadm.2014.11.007.RESEARCH IN CONTEXT
1. Systematic review: We searched PubMed for articles
with the following search terms: dementia and
screening; recognition; early or timely diagnosis; dif-
ferential diagnosis; primary care; or diagnosis rate.
In addition, we reviewed the reference lists of articles
identified.
2. Interpretation: We provided evidence that the
screening of elderly patients for dementia in primary
care practices can improve recognition of dementia
considerably. However, there is a risk that patients
receive a formal diagnosis of dementia based on a
positive screening result (without further differential
diagnostic assessment).
3. Future directions: To reduce the risk of false-positive
diagnoses, future studies should implement
screening procedures that include further differential
diagnostic. Future research needs to provide evi-
dence that screening for dementia improves health
outcomes for patients who are formally diagnosed
with dementia after they have been screened positive
for dementia.References
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